The generic drug market is growing strongly as health plan payers around the world continue to implement incentives for participants, pharmacists, doctors and others to use generic, rather than branded, medications. Facing rising patent expirations, pharmaceutical companies are diversifying into their own generics businesses, creating a vibrant market for generic drug company acquisitions as they seek to capture market share. At the same time, startups and other generic drug companies are attempting to expand, seeking capital through private investments, public offerings and other means; and government-run companies in China, Latin America and other regions are privatizing.
This is creating a vibrant environment of many different ownership structures, only some of which are well suited to the companies for which they are utilized. This report examines these ownership structures in the context of current and future industry trends, discussing current best practices through nine case studies and examining which ownership structures are most effective for which types of situations.
Key features of this report
• Identifies and analyses the most recent trends and issues in generic drug company ownership
• Describes where different ownership structures are most appropriate and useful
• Explores the complexities of key ownership structures in different world regions
• Profiles the major generic drug companies and their ownership structures
• Provides a detailed assessment of the current generic drug market including market share information and the size/growth forecasts
• Discusses how the evolving biosimilars market will impact the industry and ownership structures
To know more about this report please visit : Trends in Generics Industry Ownership: Evaluating changing industry paradigms and emerging players
Scope of this report
• Save time and money in research with the report’s up to date review and analysis of all the important trends in generic drug company ownership.
• Develop deeper insight into the size and growth of the generic drug industry by utilising the report’s unique market forecasts.
• Assess your organisation’s generic company ownership strategy by comparing it with those analyzed in the report’s 9 case studies.
• Identify the differences between different ownership structures and which best fit the needs of your organisation.
• Anticipate future generic drug company ownership trends and make your decisions as effective and economical as possible by understanding the current and future industry dynamics.
Key Market Issues
• Patent expirations
Drug makers are facing continued patent expirations of leading products, causing many to enter the generics industry themselves as a means to diversify their operations.
• Growth of generic drug usage
Around the world, generic drug usage is rising strongly as health care payers implement incentives for plan participants, pharmacists and physicians to use low cost generics rather than expensive branded drugs.
• Rising acquisitions of generic drug companies
Acquisitions of generic drug companies, particularly by Big Pharma generic divisions, are strong and rising as a means for companies to both increase revenues and achieve economies of scale.
• Increasing cross border deals
Acquirers are increasingly purchasing companies located in India, Africa and other offshore locations as the industry consolidates; this is creating more complicated ownership structures and management challenges.
• Strong offshore investment climate
In the strong economies of India and China, generic drug companies are finding increased opportunities to raise expansion capital, leading to a higher number of publicly traded companies and companies with large minority or even majority shareholders.
Key findings from this report
• Total generic drug sales reached $95b in 2009 and will expand by 7.2% per year through 2014. The Big Pharma segment is expanding most rapidly at 11.6% per year, followed by offshore generic drug companies at 9.4% per year and emerging generic drug makers at 3.4% per year.
• Most generic drug companies are privately held, but ownership structure varies with market segment.
• In the offshore region, more than one in seven generic drug makers is government owned but increased privatization is expected to provide acquisition opportunities to potential acquirers over the next few years.
• Relatively few emerging generic drug companies are publicly traded; tight capital markets combined with Big Pharma’s preference for larger acquisitions will result in increased numbers of these companies being privately held and thereby having difficulty accessing expansion capital.
• Most Big Pharma generic drug companies are wholly-owned subsidiaries; as new acquisitions are made, they tend to be folded into existing generic subsidiaries.
Key questions answered
• What will the size and growth of the total generic, offshore generic, emerging generic and Big Pharma generic markets be through 2014?
• Which companies are current and future key players?
• What kind of ownership structures will offshore generic, emerging generic and Big Pharma generic companies establish in the future?
• What are the benefits of each ownership structure for each type of generic drug company?
• What role will acquisitions play in ownership structure?
• Which ownership structures will be most effected by current economic and industry trends?
• How is investment in each ownership structure made?
To know more about this report & to buy a copy please visit :
Visionshopsters specializes in providing comprehensive collection of online market research reports, events bookings, country reports, company profiles, latest books and magazines, customized research services offering informative solutions worldwide. We constantly believe in providing inventive solutions to clients all across the globe. Our clientele consists of over thousands of top most academic organizations, financial institutions, trading companies, legal service providers, accounting consultancies and other corporate business executives.